Filippi Luca, Basile Pietro, Schillaci Orazio, Bagni Oreste
Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, Italy.
Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
Cancer Biother Radiopharm. 2020 Aug;35(6):398-403. doi: 10.1089/cbr.2019.3188. Epub 2020 Feb 28.
The aim of the study was to assess the correlation between metabolic response measured through positron emission tomography-computed tomography (PET-CT) with F choline (F FCH) and overall survival (OS) in patients affected by bone lesions from metastatic castration-resistant prostate cancer treated with Ra dichloride. Eleven subjects were subjected to PET-CT with F FCH before and 1 month after Ra treatment. Reduction in total lesion activity (ΔTLA) between pretreatment and post-treatment scan was determined and patients were divided into responders (ΔTLA >50%) and nonresponders (ΔTLA <50%). The OS of the entire cohort was 12.7 ± 3.8 months. Kaplan-Meier analysis showed that responders presented a significantly longer survival than nonresponders (16.5 ± 1.9 months vs. 10.5 ± 0.9 months, < 0.05). Reduction in TLA after Ra treatment seems to be correlated with a trend toward a longer survival.
本研究的目的是评估在接受二氯化镭治疗的转移性去势抵抗性前列腺癌骨转移患者中，通过使用氟胆碱（FCH）的正电子发射断层扫描-计算机断层扫描（PET-CT）测量的代谢反应与总生存期（OS）之间的相关性。11名受试者在镭治疗前和治疗后1个月接受了FCH-PET-CT检查。确定治疗前和治疗后扫描之间的总病灶活性降低（ΔTLA），并将患者分为反应者（ΔTLA>50%）和无反应者（ΔTLA<50%）。整个队列的总生存期为12.7±3.8个月。Kaplan-Meier分析显示，反应者的生存期明显长于无反应者（16.5±1.9个月对10.5±0.9个月，P<0.05）。镭治疗后TLA的降低似乎与生存期延长的趋势相关。
